Review Article

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

Table 2

Cumulative G3-4 toxicity according to age.
(a) Cabazitaxel

<70 years ≥70 years

Diarrhea3.3%2.2%
Fatigue4%4.3%
Asthenia1.4%4.9%
Neutropenia15%19.7%
Febrile neutropenia5.2%5.5%
Anemia5%4.3%

(b) Enzalutamide

≥75 years<75 years

Fatigue40%32%
Nausea32%33%